Skip to main content
Top

Open Access 10-04-2025 | Vasculitis | Original Article

Long Term Follow-Up of Patients with Cryoglobulinemia After Successful Treatment of Chronic C Virus Hepatitis

Authors: Bianka Zsuzsa Elthes, Zsuzsanna Vitalis, Maria Papp, Tamas Tornai, David Tornai, Istvan Tornai

Published in: Digestive Diseases and Sciences

Login to get access

Abstract

Background

Mixed cryoglobulinemia is one of the most important extrahepatic manifestations of chronic hepatitis C infection.

Aims and Methods

We screened 111 HCV-infected patients and identified 40 with cryoglobulinemia, who later achieved sustained virologic response (SVR). We prospectively followed them regarding laboratory findings and clinical symptoms for a median [IQR] of 5 [3–10] years.

Results

Prior to antiviral treatment, the median serum cryoglobulin level was 297 (IQR: 61–1144) mg/L. In 25 patients type II, while in 15 type III cryoglobulinemia were found with significant difference in cryoglobulin levels (669 [297–2713] vs. 57 [33–123], respectively) (p < 0.001). Only 23 patients had clinical symptoms at the diagnosis, of whom 21 had cryoglobulinemic vasculitis and 2 non-Hodgkin's lymphoma (NHL), and 17 patients were asymptomatic. Cryoglobulin levels were monitored yearly after SVR. Median times to cryoglobulin disappearance were significantly different between type II and type III disease forms (36 vs. 12 months, pLog-Rank: 0.002). Improvement or complete cessation of complaints were parallel to the cryoglobulin disappearance. Vasculitis, in most cases (n = 16) and one NHL were cured spontaneously during follow-up observation. However, some patients required specific treatment, such as immunosuppression [n = 5] for vasculitis and combined chemotherapy [n = 1] for aggressive NHL. Relapses of cryoglobulinemia and related symptoms were detected in 2 patients. Importantly, polyneuropathy did not show improvement by any means.

Conclusions

Our results support that the monitoring of cryoglobulins is important even after SVR, especially in case of type II forms. Long-term complications such as severe vasculitis or NHL may still occur.
Literature
1.
go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.CrossRefPubMed Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–1342.CrossRefPubMed
2.
go back to reference AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.CrossRef AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.CrossRef
3.
go back to reference Denniston MM, Jiles RB, Drobeniuc J et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.CrossRefPubMedPubMedCentral Denniston MM, Jiles RB, Drobeniuc J et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293–300.CrossRefPubMedPubMedCentral
5.
go back to reference Cacoub P, Vieira M. Saadoun D Cryoglobulinemia-One Name for Two Diseases. N Engl J Med. 2024;391:1426–1439.CrossRefPubMed Cacoub P, Vieira M. Saadoun D Cryoglobulinemia-One Name for Two Diseases. N Engl J Med. 2024;391:1426–1439.CrossRefPubMed
6.
go back to reference Damoiseaux J, Tervaert JWC. Diagnostics and Treatment of Cryoglobulinemia: It Takes Two to Tango. Clin Rev Allergy Immunol. 2014;47:299–310.CrossRefPubMed Damoiseaux J, Tervaert JWC. Diagnostics and Treatment of Cryoglobulinemia: It Takes Two to Tango. Clin Rev Allergy Immunol. 2014;47:299–310.CrossRefPubMed
7.
go back to reference Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384:1038–1052.CrossRefPubMed Cacoub P, Saadoun D. Extrahepatic manifestations of chronic HCV infection. N Engl J Med. 2021;384:1038–1052.CrossRefPubMed
8.
go back to reference Monti G, Pioltelli P, Saccardo F et al. Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus-Related Symptomatic Mixed Cryoglobulinemias. Arch Intern Med. 2005;165:101–105.CrossRefPubMed Monti G, Pioltelli P, Saccardo F et al. Incidence and Characteristics of Non-Hodgkin Lymphomas in a Multicenter Case File of Patients With Hepatitis C Virus-Related Symptomatic Mixed Cryoglobulinemias. Arch Intern Med. 2005;165:101–105.CrossRefPubMed
9.
go back to reference Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–2085.CrossRef Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2006;15:2078–2085.CrossRef
10.
go back to reference Cheng YT, Cheng JS, Lin CH, Chen TH, Lee KC, Chang ML. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinemia: an 8-year prospective study. Clin Microbiol Infect. 2020;26:366–372.CrossRefPubMed Cheng YT, Cheng JS, Lin CH, Chen TH, Lee KC, Chang ML. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinemia: an 8-year prospective study. Clin Microbiol Infect. 2020;26:366–372.CrossRefPubMed
11.
go back to reference Comarmond C, Garrido M, Pol S et al. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Gastroenterology. 2017;152:2052-2062.e2.CrossRefPubMed Comarmond C, Garrido M, Pol S et al. Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis. Gastroenterology. 2017;152:2052-2062.e2.CrossRefPubMed
12.
go back to reference Visentini M, Del Padre M, Colantuono S et al. Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. Liver Int. 2019;39:628–632.CrossRefPubMed Visentini M, Del Padre M, Colantuono S et al. Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis. Liver Int. 2019;39:628–632.CrossRefPubMed
13.
go back to reference Cacoub P, Si Ahmed SN, Ferfar Y et al. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2019;17:518–526.CrossRefPubMed Cacoub P, Si Ahmed SN, Ferfar Y et al. Long-term Efficacy of Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2019;17:518–526.CrossRefPubMed
14.
go back to reference Bonacci M, Lens S, Mariño Z et al. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology. 2018;155:311-315.e6.CrossRefPubMed Bonacci M, Lens S, Mariño Z et al. Long-Term Outcomes of Patients With HCV-Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology. 2018;155:311-315.e6.CrossRefPubMed
15.
go back to reference Fayed A, Hegazy MT, Biard L et al. Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. Am J Gastroenterol. 2022;117:627–636.CrossRefPubMed Fayed A, Hegazy MT, Biard L et al. Relapse of Hepatitis C Virus Cryoglobulinemic Vasculitis After Sustained Viral Response After Interferon-Free Direct-Acting Antivirals. Am J Gastroenterol. 2022;117:627–636.CrossRefPubMed
16.
go back to reference Musset L, Diemert MC, Taibi F et al. Characterisation of cryoglobulins by immunoblotting. Clin Chem. 1992;38:798–802.CrossRefPubMed Musset L, Diemert MC, Taibi F et al. Characterisation of cryoglobulins by immunoblotting. Clin Chem. 1992;38:798–802.CrossRefPubMed
17.
go back to reference Stoyanov A, Toong C, Kong Y, Chen R, Urriola N. Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia. Pathology 2023;55:391–396.CrossRefPubMed Stoyanov A, Toong C, Kong Y, Chen R, Urriola N. Serum protein electrophoresis and rheumatoid factor analysis is an effective screening strategy for cryoglobulinaemia. Pathology 2023;55:391–396.CrossRefPubMed
18.
go back to reference Mazzaro C, Zorat F, Comar C et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003;30:1775–1781.PubMed Mazzaro C, Zorat F, Comar C et al. Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 2003;30:1775–1781.PubMed
19.
go back to reference Cacoub P, Lidove O, Maisonobe T et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46:3317–3326.CrossRefPubMed Cacoub P, Lidove O, Maisonobe T et al. Interferon-α and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum. 2002;46:3317–3326.CrossRefPubMed
20.
go back to reference Mazzaro C, Monti G, Saccardo F et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clinical and Experimental Rheumatology. 2011;29:933–941.PubMed Mazzaro C, Monti G, Saccardo F et al. Efficacy and safety of peginterferon alfa-2b plus ribavirin for HCV-positive mixed cryoglobulinemia: a multicentre open-label study. Clinical and Experimental Rheumatology. 2011;29:933–941.PubMed
21.
go back to reference Gragnani L, Fognani E, Piluso A, MaSVE Study Group et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61:1145–1153.CrossRefPubMed Gragnani L, Fognani E, Piluso A, MaSVE Study Group et al. Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study. Hepatology. 2015;61:1145–1153.CrossRefPubMed
22.
go back to reference Mazzaro C, Dal Maso L, Mauro E et al. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. Autoimmun Rev. 2020;19:102589.CrossRefPubMed Mazzaro C, Dal Maso L, Mauro E et al. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. Autoimmun Rev. 2020;19:102589.CrossRefPubMed
23.
go back to reference Sise ME, Bloom AK, Wisocky J et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–417.CrossRefPubMed Sise ME, Bloom AK, Wisocky J et al. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63:408–417.CrossRefPubMed
24.
go back to reference Gragnani L, Visentini M, Fognani E et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–1482.CrossRefPubMed Gragnani L, Visentini M, Fognani E et al. Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia. Hepatology. 2016;64:1473–1482.CrossRefPubMed
25.
go back to reference Bonacci M, Lens S, Londoño MC et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.e1.CrossRefPubMed Bonacci M, Lens S, Londoño MC et al. Virologic, Clinical, and Immune Response Outcomes of Patients With Hepatitis C Virus-Associated Cryoglobulinemia Treated With Direct-Acting Antivirals. Clin Gastroenterol Hepatol. 2017;15:575-583.e1.CrossRefPubMed
26.
go back to reference Comarmond C, Cacoub P, Saadoun D. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol. 2020;13:1756284820942617.CrossRefPubMedPubMedCentral Comarmond C, Cacoub P, Saadoun D. Treatment of chronic hepatitis C-associated cryoglobulinemia vasculitis at the era of direct-acting antivirals. Therap Adv Gastroenterol. 2020;13:1756284820942617.CrossRefPubMedPubMedCentral
28.
go back to reference Chang ML, Cheng JS, Chuang YH et al. Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study. Front Immunol. 2022;13:823160.CrossRefPubMedPubMedCentral Chang ML, Cheng JS, Chuang YH et al. Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study. Front Immunol. 2022;13:823160.CrossRefPubMedPubMedCentral
29.
go back to reference Kondili LA, Monti M, Quaranta MG et al. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2022;76:220–232.CrossRefPubMed Kondili LA, Monti M, Quaranta MG et al. A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology. 2022;76:220–232.CrossRefPubMed
Metadata
Title
Long Term Follow-Up of Patients with Cryoglobulinemia After Successful Treatment of Chronic C Virus Hepatitis
Authors
Bianka Zsuzsa Elthes
Zsuzsanna Vitalis
Maria Papp
Tamas Tornai
David Tornai
Istvan Tornai
Publication date
10-04-2025
Publisher
Springer US
Published in
Digestive Diseases and Sciences
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-025-09033-8

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar